Navigation Links
BiondVax Receives Additional Grant Approval
Date:2/18/2016

NESS ZIONA, Israel, February 18, 2016 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the National Authority for Technological Innovation (NATI), formerly known as the Office of the Chief Scientist, agreed to fund up to 40% of a NIS 3.6 million (US$920,000) project towards ongoing development of the Company's Universal Flu Vaccine.

Currently undergoing late Phase 2 clinical trials, BiondVax's vaccine has shown significantly increased effectiveness against multiple seasonal and pandemic flu strains when compared to today's existing flu vaccines.  With today's grant approval, NATI has, since 2006, granted $5.5M to BiondVax. The non-dilutive grants are repayable from royalties generated from future sales of BiondVax's vaccine, once available on the market.

Ron Babecoff, CEO of BiondVax commented, "The continued support of our program by NATI represents a strong and ongoing vote of confidence in BiondVax and what we are aiming to achieve. They were impressed with the positive results from our five completed clinical trials to-date, and strongly support our current and planned activities."

About BiondVax Pharmaceuticals Ltd. 

BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit http://www.biondvax.com.

Forward Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug development involves a lengthy and expensive process with uncertain outcome, the timing of the receipt of the grant funds, risks inherent in the development and commercialization of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements. 

For further information, please contact:

Company Contact
Joshua Phillipson
Business Development  Manager
+972-8-930-2529 x5105
j.phillipson@biondvax.com

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
kenny@biondvax.com


'/>"/>
SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. BiondVax Pharmaceuticals Ltd. Announces a Closing of Over-Allotment Option
2. BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults
3. Independent Results Show that BiondVaxs Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic
4. BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
5. BiondVax to Present on October 8 at the Aegis Growth Conference
6. Biondvaxs Universal Flu Vaccine Receives Additional US Patent
7. IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit
8. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System
11. BioElectronics Receives Working Capital Infusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... The National Comprehensive ... Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR to ... NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with CureMD ...
(Date:6/11/2019)... ... 2019 , ... SABRE , the leading brand in personal safety and ... showcase their latest and most innovative personal safety products, including the Mighty Discreet ... Summer Market 2019 (Booth #39158-UL), June 18-20 in Denver, CO. , SABRE’s ...
(Date:6/6/2019)... OAKLAND, Calif. (PRWEB) , ... June 06, 2019 , ... ... to further curtail US travel to Cuba. “This latest move is one more assault ... the island,” said Dr. Peter G. Bourne, Chair of MEDICC’s Board of Directors. ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... The University of Pittsburgh School of Health and ... Informatics (MSHI ) degree program to address the growing need for professionals who can ... of a larger effort for SHRS to bring more graduate degrees online. The Master ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... tissue fabrication, patient-matched models and surgical guides, and prosthetics and assistive devices—are ... patient care. Children with birth defects, soldiers with cranial injuries, conjoined twins, ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... with caregivers and dementia patients to deteriorate. , Researchers from the University ... survey with professional caregivers who care for people who have dementia and experienced ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... Miller, a quality assurance expert with more than 25 years of experience in ... Compliance for all classes of medical devices, has joined NDA Partners as an ...
(Date:6/12/2019)... ... 12, 2019 , ... In September of 2018, NVNA and Hospice (NVNA) partnered ... patient monitoring. Following its full-scale launch in March, NVNA has expanded its program with ... of 2019, NVNA has achieved an average all-cause hospital readmissions rate of 7.3% and ...
Breaking Medicine News(10 mins):